Navigation Links
diaDexus Announces Name Change From VaxGen
Date:11/1/2010

ment and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC ELISA Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. For more information, please visit the company's website at www.diaDexus.com

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products and other statements that are not historical in nature, particularly those that use terminology such as "will," "potential", "prospects," "could," "can," "believe," "intends," "continue," "plans," "expects," "estimates" or comparable terminology. Forward-looking statements are based on current expectations and assumptions, and entail various known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to diaDexus that could cause actual results to differ materially from those expressed in such forward-looking statements include risks related to general business and economic conditions; the failure to realize the anticipated benefits from the company's acquisition of the former diaDexus, Inc.;  the technical and commercial merits and potential of the company's diagnostic products; and the difficulty of developing pharmaceutical and diagnostic products, obtaining and maintaining regulatory and other approvals and achieving market acceptance. Additional factors that could cause diaDexus' results to
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the ... Annual Meeting of Stockholders on May 4, 2015 (the ... the Annual Meeting represents a change of more than ...
(Date:12/24/2014)... December 23, 2014 ... is designed to introduce cutting edge communication ... and partners of platform upgrades. This webinar ... empowering users in their quest to leverage ... , According to SoundConnect’s Marketing Manager, Seanna ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... delivery of exenatide produces impressive reductions in fasting plasma ... , NEW ORLEANS, June 8 Intarcia Therapeutics, ... of ITCA 650 (DUROS(R) continuous delivery of exenatide) for ... at the Annual Conference of the American Diabetes Association ...
... Pharmaceuticals today announced that new clinical and preclinical ... cell selectivity of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in ... the European Hematology Association (EHA) in Berlin, Germany, ... , "These findings underscore the potential pharmacological ...
... , All amounts are in US dollars , ... Inc. (NASDAQ: AEZS ; TSX: AEZ), a ... today reported that after regaining from Ardana Biosciences Ltd. ... ("GHS") / ghrelin agonist, AEZS-130, it has entered into ...
Cached Biology Technology:Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 2Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 3Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 4Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 2Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 3AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 2AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 3
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... A NASA-led study has documented an unprecedented depletion of the ... spring that was caused by an unusually prolonged period of ... physicist Kaley Walker was part of the international team behind ... Nature . The researchers found the amount of ...
... Institute for Genomic Biology (IGB) and the School of ... Integrative Graduate Education and Research Traineeship (IGERT) is a ... and has, thus far, provided interdisciplinary research training to ... Illinois grant, Vertically Integrated Training With Genomics (VInTG), will ...
... determined that a combination of P16 immunohistochemistry and DNA ... the oropharyngeal squamous cell carcinoma, a form of head ... a study published in Clinical Cancer Research , ... "This has immediate clinical applications as we consider ...
Cached Biology News:Unprecedented Arctic ozone loss occurred last winter 2Unprecedented Arctic ozone loss occurred last winter 3Institute for Genomic Biology, School of Integrative Biology receive major NSF training grant 2